Operating Income (Loss) of Enlivex Therapeutics Ltd. from 31 Dec 2012 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Enlivex Therapeutics Ltd. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2012 to 30 Jun 2025.
  • Enlivex Therapeutics Ltd. Operating Income (Loss) for the quarter ending 30 Jun 2025 was $3,078,000, a 3.1% decline year-over-year.
  • Enlivex Therapeutics Ltd. annual Operating Income (Loss) for 2024 was $15,888,000, a 46% increase from 2023.
  • Enlivex Therapeutics Ltd. annual Operating Income (Loss) for 2023 was $29,395,000, a 14% decline from 2022.
  • Enlivex Therapeutics Ltd. annual Operating Income (Loss) for 2022 was $25,797,000, a 34% decline from 2021.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Enlivex Therapeutics Ltd. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $3,078,000 -$92,000 -3.1% 01 Apr 2025 30 Jun 2025 6-K 29 Aug 2025 2025 Q2
Q2 2024 $2,986,000 +$3,663,000 +55% 01 Apr 2024 30 Jun 2024 6-K 29 Aug 2025 2025 Q2
Q2 2023 $6,649,000 -$778,000 -13% 01 Apr 2023 30 Jun 2023 6-K 30 Aug 2024 2024 Q2
Q2 2022 $5,871,000 -$2,063,000 -54% 01 Apr 2022 30 Jun 2022 6-K 01 Sep 2023 2023 Q2
Q2 2021 $3,808,000 -$1,575,000 -71% 01 Apr 2021 30 Jun 2021 6-K 22 Aug 2022 2022 Q2
Q2 2020 $2,233,000 -$936,000 -72% 01 Apr 2020 30 Jun 2020 6-K 06 Aug 2021 2021 Q2
Q2 2019 $1,297,000 01 Apr 2019 30 Jun 2019 6-K/A 13 Oct 2020 2020 Q2
Q4 2016 $15,866,000 $3,074,000 +$1,759,000 +36% 01 Oct 2016 31 Dec 2016 20-F 24 Feb 2017 2016 FY
Q3 2016 $17,625,000 $4,578,000 -$991,000 -28% 01 Jul 2016 30 Sep 2016 20-F 24 Feb 2017 2016 FY
Q2 2016 $16,634,000 $3,722,000 +$16,000 +0.43% 01 Apr 2016 30 Jun 2016 20-F 24 Feb 2017 2016 FY
Q1 2016 $16,650,000 $4,492,000 -$1,174,000 -35% 01 Jan 2016 31 Mar 2016 20-F 24 Feb 2017 2016 FY
Q4 2015 $15,476,000 $4,833,000 01 Oct 2015 31 Dec 2015 20-F 24 Feb 2017 2016 FY
Q3 2015 $3,587,000 01 Jul 2015 30 Sep 2015 20-F 24 Feb 2017 2016 FY
Q2 2015 $3,738,000 01 Apr 2015 30 Jun 2015 20-F 24 Feb 2017 2016 FY
Q1 2015 $3,318,000 01 Jan 2015 31 Mar 2015 20-F 24 Feb 2017 2016 FY

Enlivex Therapeutics Ltd. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,888,000 +$13,507,000 +46% 01 Jan 2024 31 Dec 2024 20-F 30 Apr 2025 2024 FY
2023 $29,395,000 -$3,598,000 -14% 01 Jan 2023 31 Dec 2023 20-F 30 Apr 2025 2024 FY
2022 $25,797,000 -$6,509,000 -34% 01 Jan 2022 31 Dec 2022 20-F 30 Apr 2025 2024 FY
2021 $19,288,000 -$9,503,000 -97% 01 Jan 2021 31 Dec 2021 20-F 30 Apr 2024 2023 FY
2020 $9,785,000 -$1,166,000 -14% 01 Jan 2020 31 Dec 2020 20-F 10 Apr 2023 2022 FY
2019 $8,619,000 -$3,320,000 -63% 01 Jan 2019 31 Dec 2019 20-F 29 Apr 2022 2021 FY
2018 $5,299,000 -$3,128,000 -144% 01 Jan 2018 31 Dec 2018 20-F 30 Apr 2021 2020 FY
2017 $2,171,000 +$13,695,000 +86% 01 Jan 2017 31 Dec 2017 20-F 30 Apr 2020 2019 FY
2016 $15,866,000 -$390,000 -2.5% 01 Jan 2016 31 Dec 2016 20-F/A 23 Jan 2020 2018 FY
2015 $15,476,000 -$8,396,000 -119% 01 Jan 2015 31 Dec 2015 20-F 23 Apr 2018 2017 FY
2014 $7,080,000 -$5,932,000 -517% 01 Jan 2014 31 Dec 2014 20-F 24 Feb 2017 2016 FY
2013 $1,148,000 -$922,000 -408% 01 Jan 2013 31 Dec 2013 20-F 29 Mar 2016 2015 FY
2012 $226,000 01 Jan 2012 31 Dec 2012 20-F 31 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.